BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) developing the first-of-its-kind bioartificial liver device intended for the treatment of liver failure, announced today that the Company has completed a Private Placement of its securities consisting of shares and warrants to institutional and accredited investors for aggregate gross proceeds of approximately $4,530,000. Palladium Capital Advisors, LLC, a FINRA/SIPC member firm, acted as placement agent.
